Table 6. Incidence of sorafenib-related adverse events in the TACE-sorafenib group.

Adverse events	All grade,	Grade 1-2,	Grade 3,	Grade 4,
	n (%)	n (%)	n (%)	n (%)
Hand-foot skin reaction	83 (80.6%)	74 (71.8%)	9 (8.7%)	0
Diarrhea	66 (64.1%)	66 (64.1%)	0	0
Fatigue	25 (24.3%)	25 (24.3%)	0	0
Hypertension	9 (8.7%)	7 (6.8%)	2 (1.9%)	0
Rash	8 (7.8%)	8 (7.8%)	0	0
Alopecia	22 (21.4%)	22 (21.4%)	0	0
Voice changes	2 (1.9%)	2 (1.9%)	0	0